EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 377 filers reported holding EXELIXIS INC in Q2 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $12,695,550 | -11.8% | 565,000 | -6.8% | 0.03% | -3.2% |
Q1 2024 | $14,387,499 | +252.1% | 606,300 | +255.9% | 0.03% | +244.4% |
Q4 2023 | $4,086,529 | +11.4% | 170,343 | +1.5% | 0.01% | -10.0% |
Q3 2023 | $3,668,593 | +742.4% | 167,899 | +636.8% | 0.01% | +900.0% |
Q2 2023 | $435,498 | +104.0% | 22,789 | +107.2% | 0.00% | – |
Q1 2023 | $213,510 | -66.7% | 11,000 | -73.1% | 0.00% | -100.0% |
Q3 2022 | $642,000 | -57.1% | 40,947 | -43.0% | 0.00% | -60.0% |
Q2 2022 | $1,495,000 | -32.3% | 71,808 | -26.3% | 0.01% | -28.6% |
Q1 2022 | $2,208,000 | +210.5% | 97,398 | +150.6% | 0.01% | +250.0% |
Q4 2021 | $711,000 | -75.3% | 38,870 | -71.5% | 0.00% | -80.0% |
Q3 2021 | $2,879,000 | +457.9% | 136,200 | +381.3% | 0.01% | +233.3% |
Q2 2021 | $516,000 | +64.3% | 28,301 | +103.9% | 0.00% | +200.0% |
Q1 2021 | $314,000 | -83.8% | 13,879 | -85.6% | 0.00% | -87.5% |
Q4 2020 | $1,937,000 | +15.8% | 96,542 | +41.1% | 0.01% | -11.1% |
Q3 2020 | $1,672,000 | -11.7% | 68,400 | -37.8% | 0.01% | -35.7% |
Q1 2020 | $1,893,000 | -60.3% | 109,937 | -59.4% | 0.01% | -57.6% |
Q4 2019 | $4,766,000 | +478.4% | 270,500 | +480.6% | 0.03% | +371.4% |
Q3 2019 | $824,000 | -31.3% | 46,587 | -17.1% | 0.01% | -30.0% |
Q2 2019 | $1,200,000 | -45.8% | 56,200 | -39.6% | 0.01% | -44.4% |
Q1 2019 | $2,216,000 | -32.9% | 93,100 | -44.6% | 0.02% | -25.0% |
Q4 2018 | $3,303,000 | +1118.8% | 167,944 | +997.7% | 0.02% | +1100.0% |
Q3 2018 | $271,000 | -74.7% | 15,300 | -69.3% | 0.00% | -66.7% |
Q2 2018 | $1,073,000 | -54.2% | 49,848 | -52.8% | 0.01% | -57.1% |
Q1 2018 | $2,341,000 | +197.5% | 105,700 | +308.3% | 0.01% | +250.0% |
Q4 2017 | $787,000 | +86.9% | 25,885 | +51.3% | 0.00% | +33.3% |
Q2 2017 | $421,000 | +3727.3% | 17,105 | +3321.0% | 0.00% | – |
Q1 2017 | $11,000 | -76.1% | 500 | -83.9% | 0.00% | – |
Q4 2016 | $46,000 | -62.9% | 3,100 | -68.0% | 0.00% | -100.0% |
Q3 2016 | $124,000 | +12300.0% | 9,700 | +9600.0% | 0.00% | – |
Q2 2016 | $1,000 | -95.5% | 100 | -97.4% | 0.00% | – |
Q3 2015 | $22,000 | – | 3,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |